Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Middleton

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
European Journal of Cancer (Oxford, England : 1990)|August 31, 2010
A phase 2 study of vatalanib in metastatic melanoma patientsNatalie Cook, Bristi Basu, Swethajit Biswas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2020
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid TumorsRichard D Baird, Constanza Linossi, Mark Middleton, et al.
Cancer Cell|June 25, 2013
Directed phenotype switching as an effective antimelanoma strategyMagalí Sáez-Ayala, María F Montenegro, Luis Sánchez-Del-Campo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumorsRuth Plummer, Christopher Jones, Mark Middleton, et al.
Plos Medicine|February 15, 2017
Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health ServiceAngela Hamblin, Sarah Wordsworth, Jilles M Fermont, et al.
Frontiers in Toxicology|March 10, 2025
Evaluation of a non-animal toolbox informed by adverse outcome pathways for human inhalation safetyRenato Ivan de Ávila, Iris Müller, Hugh Barlow, et al.
International Journal of Cancer|August 2, 2014
NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virusJi-Li Chen, Amina Dawoodji, Andrea Tarlton, et al.
NPJ Breast Cancer|April 8, 2022
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancerMelinda L Telli, Sara M Tolaney, Geoffrey I Shapiro, et al.
Nature Communications|April 6, 2016
Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapyJohn M Findlay, Francesc Castro-Giner, Seiko Makino, et al.
Healthcare (Basel, Switzerland)|September 23, 2022
How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?Denis Horgan, Anne-Marie Baird, Mark Middleton, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
European Journal of Cancer (Oxford, England : 1990)|August 31, 2010
A phase 2 study of vatalanib in metastatic melanoma patientsNatalie Cook, Bristi Basu, Swethajit Biswas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2020
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid TumorsRichard D Baird, Constanza Linossi, Mark Middleton, et al.
Cancer Cell|June 25, 2013
Directed phenotype switching as an effective antimelanoma strategyMagalí Sáez-Ayala, María F Montenegro, Luis Sánchez-Del-Campo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumorsRuth Plummer, Christopher Jones, Mark Middleton, et al.
Plos Medicine|February 15, 2017
Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health ServiceAngela Hamblin, Sarah Wordsworth, Jilles M Fermont, et al.
Frontiers in Toxicology|March 10, 2025
Evaluation of a non-animal toolbox informed by adverse outcome pathways for human inhalation safetyRenato Ivan de Ávila, Iris Müller, Hugh Barlow, et al.
International Journal of Cancer|August 2, 2014
NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virusJi-Li Chen, Amina Dawoodji, Andrea Tarlton, et al.
NPJ Breast Cancer|April 8, 2022
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancerMelinda L Telli, Sara M Tolaney, Geoffrey I Shapiro, et al.
Nature Communications|April 6, 2016
Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapyJohn M Findlay, Francesc Castro-Giner, Seiko Makino, et al.
Healthcare (Basel, Switzerland)|September 23, 2022
How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?Denis Horgan, Anne-Marie Baird, Mark Middleton, et al.
Pageof 6